Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials

Carla Casulo, MD, Jennifer Le-Rademacher, PhD, Jesse Dixon, Stat, Gilles Salles, MD, Eva Hoster, Michael Herold, MD, Wolfgang Hiddemann, Catherine Sebban, MD, Robert Marcus, Eva Kimby, Howard Hochster, MD, Umberto Vitolo, MD, Emmanuel Gyan, MDPhD, Fang-Shu Ou, PhD, Tina Nielsen, Kenneth A. Foon, MD, Shi Qiuan, PhD, Christopher Flowers, MD

Blood (2017) 130 (Supplement 1): 412.

https://doi.org/10.1182/blood.V130.Suppl_1.412.412

Published: 2017

Journal Articles

MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

David J. Andorsky, MD, Abdulraheem Yacoub, MD, Jacob D. Bitran, MD, Jason Melear, MD, Heather D. Brooks, MD BS, BA, Kenneth A. Foon, MD, Syed Rizvi, MD, Mary Llorente, Jiahui Li, PhD, Jeff P. Sharman, MD

Blood (2016) 128 (22): 1798.

https://doi.org/10.1182/blood.V128.22.1798.1798

Published: 2016

Journal Articles

A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR 2 Regimen

Anthony R. Mato, MD MSCE, Kenneth A. Foon, MD, Tatyana Feldman, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Kar Fai Chow, MD, Marisa Valentinetti, BS, Mary Morin, BS, Kelly Azzollini, BS, Gabriella Magarelli, MS, Pritish K. Bhattacharyya, MD, Joshua Zenreich, BS, Christina Howlett, PharmD, BCOP, Lauren-Nicole Pascual, BS, Kara Yanotti, BSN, Sabrina Kdiry, BSN, David Porter, MD, Andre Goy, MD

Blood (2014) 124 (21): 4678.

https://doi.org/10.1182/blood.V124.21.4678.4678

Published: 2014

Journal Articles

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia

Kenneth A. Foon, Dhaval Mehta, Suzanne Lentzsch, Patricia Kropf, Stanley Marks, Diana Lenzner, Louis Pietragallo, Mathew Sulecki, Ahmad Tarhini, Michael Boyiadzis

Blood (2012) 119 (13): 3184–3185.

https://doi.org/10.1182/blood-2012-01-408047

Published: 2012

Journal Articles

Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIP™ Protein In Relapsed and Refractory CLL

Richard R. Furman, MD, Leslie Andritsos, MD, Ian W. Flinn, MD, PhD, Andres Forero-Torres, MD, Kenneth A. Foon, MD, John M. Pagel, MD, PhD, Anil Singhal, MD, Scott C. Stromatt, MD, John C. Byrd, MD

Blood (2010) 116 (21): 56.

https://doi.org/10.1182/blood.V116.21.56.56

Published: 2010

Journal Articles

A Randomized Controlled Trial of Spiritually-Focused Meditation In Patients Newly Diagnosed with Acute Leukemia.

Brenda Cole, Karen Broer, Clare Hopkins, John Tisak, Ryan Hunt, Chris McNally, Mikkael Sekeres, Kenneth A. Foon, Michael Boyiadzis

Blood (2010) 116 (21): 1519.

https://doi.org/10.1182/blood.V116.21.1519.1519

Published: 2010

Journal Articles

Clearly defined response criteria evaluating treatment of CLL patients in clinical research trials

Kenneth A. Foon

Blood (2010) 116 (10): 1817.

https://doi.org/10.1182/blood-2010-03-274035

Published: 2010

Journal Articles

Phase II Study of Short Course CHOP-Rituximab Followed by 90-Y Ibritumomab Tiuxetan as First-Line Treatment for Follicular Lymphoma: An Update and Extension of Preliminary Findings on Predictors of Relapse.

Rachel C. Jankowitz, MD, Kenneth A. Foon, MD, The Minh Luong, M.Sc, Stephanie R. Land, PhD, Nicholas A. DeMonaco, MD, Steven H. Swerdlow, MD, Judith Joyce, MD, Jennifer Osborn, MD, Terry Evans, MD, Samuel A. Jacobs, MD

Blood (2008) 112 (11): 2001.

https://doi.org/10.1182/blood.V112.11.2001.2001

Published: 2008

Journal Articles

Flow cytometric immunophenotyping for hematologic neoplasms

Fiona E. Craig, Kenneth A. Foon

Blood (2008) 111 (8): 3941–3967.

https://doi.org/10.1182/blood-2007-11-120535

Published: 2008

Journal Articles

Final Results of Lower Dose Fludarabine (F) and Cyclophosphamide (C), and High Dose Rituximab (R), (FCR-Lite) for Patients with Untreated Chronic Lymphocytic Leukemia (CLL).

Ahmad A. Tarhini, MD, MSc, S. Land, L. Pietragallo, MD, A. Laman, MD, M. Sulecki, MD, S. Marks, MD, D. Meisner, MD, P.M. Schaefer, RN, Kenneth A. Foon, MD

Blood (2007) 110 (11): 2037.

https://doi.org/10.1182/blood.V110.11.2037.2037

Published: 2007

Journal Articles

Generation of alpha-Type-1 Polarized Dendritic Cells as a Potent Immunogen in Patients with Chronic Lymphocytic Leukemia.

Je-Jung Lee, MD, PhD, Robbie Mailliard, PhD, Ravikumar Muthuswamy, PhD, Kenneth A. Foon, MD, PhD, Pawel Kalinski, MD, PhD

Blood (2007) 110 (11): 2059.

https://doi.org/10.1182/blood.V110.11.2059.2059

Published: 2007

Journal Articles

Interleukin-15 Upregulates the Expression of NK-Cell Activating Receptors and Concomitantly Increases the NK Cytotoxicity in Patients with Acute Myeloid Leukemia.

Miroslaw J. Szczepanski, MD, Malgorzata Czystowska, PhD, Marta Szajnik, MD, PhD, Ann Welsh, Kenneth A. Foon, MD, Theresa L. Whiteside, PhD, Michael Boyiadzis, MD

Blood (2007) 110 (11): 2298.

https://doi.org/10.1182/blood.V110.11.2298.2298

Published: 2007

Journal Articles

CD4+ CD25 high Regulatory T Cells in Newly Diagnosed Patients with Acute Myeloid Leukemia.

Miroslaw J. Szczepanski, MD, Laura Strauss, PhD, Malgorzata Czystowska, PhD, Marta Szajnik, MD, PhD, Ann Welsh, Kenneth A. Foon, MD, Theresa L. Whiteside, PhD, Michael Boyiadzis, MD

Blood (2007) 110 (11): 2835.

https://doi.org/10.1182/blood.V110.11.2835.2835

Published: 2007

Journal Articles

Efficacy of Mitoxantrone and Etoposide in Patients with Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy.

Rajesh Sehgal, MD, Wassim McHayleh, MD, James Natale, Anastasios Raptis, MD, Mounzer Agha, MD, Robert L. Redner, MD, Gene Richard, Ann Welsh, Kenneth A. Foon, MD, Michael Boyiadzis, MD

Blood (2007) 110 (11): 4385.

https://doi.org/10.1182/blood.V110.11.4385.4385

Published: 2007

Journal Articles

Early Clinical and Pharmacokinetic Results of Lower Dose Fludarabine and Cyclophosphamide, and High Dose Rituximab (FCR-Lite) for Patients with Untreated Chronic Lymphocytic Leukemia (CLL).

Ahmad A. Tarhini, MD, S. Land, ScD, D. Meisner, MD, L. Pietragallo, MD, M. Sulecki, MD, F. Lim, MD, Gauri J. Kiefer, MD, R. Pinkerton, MD, J. Obsorn, MD, S. Sukaly, BS, P.M. Schaefer, RN, Kenneth A. Foon, MD

Blood (2006) 108 (11): 2844.

https://doi.org/10.1182/blood.V108.11.2844.2844

Published: 2006

Journal Articles

The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL

Anthony G. Brickner, Anne M. Evans, Jeffrey K. Mito, Suzanne M. Xuereb, Xin Feng, Tetsuya Nishida, Liane Fairfull, Robert E. Ferrell, Kenneth A. Foon, Donald F. Hunt, Jeffrey Shabanowitz, Victor H. Engelhard, Stanley R. Riddell, Edus H. Warren

Blood (2006) 107 (9): 3779–3786.

https://doi.org/10.1182/blood-2005-08-3501

Published: 2006

Journal Articles

Phase II Trial of Abbreviated CHOP-Rituximab Followed by 90 Y Ibritumomab Tiuxetan (Zevalin) and Rituximab in Patients with Previously-Untreated Follicular Non-Hodgkin Lymphoma (NHL).

Nicholas A. DeMonaco, MD, Michael Wu, MD, Jennifer Osborn, MD, Terry Evans, MD, Kenneth A. Foon, MD, Steven H. Swerdlow, MD, Jeffrey Kant, MD, PhD, Judith Joyce, MD, Stephanie R. Land, PhD, Samuel A. Jacobs, MD

Blood (2005) 106 (11): 2449.

https://doi.org/10.1182/blood.V106.11.2449.2449

Published: 2005

Journal Articles

An Alternative Transcript of the PANE1 Gene Encodes a Minor Histocompatibility Antigen That Is Selectively Expressed in Resting CD19 + Cells and B-CLL.

Anthony G. Brickner, PhD, Jeffrey K. Mito, Xin Feng, MD, Tetsuya Nishida, PhD, Liane Fairfull, Robert E. Ferrell, PhD, Kenneth A. Foon, MD, Stanley R. Riddell, MD, Edus H. Warren, MD, PhD

Blood (2005) 106 (11): 2957.

https://doi.org/10.1182/blood.V106.11.2957.2957

Published: 2005

Journal Articles

Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules

Claudia Palena, Kenneth A. Foon, Dennis Panicali, Alicia Gómez Yafal, Jarasvech Chinsangaram, James W. Hodge, Jeffrey Schlom, Kwong Y. Tsang

Blood (2005) 106 (10): 3515–3523.

https://doi.org/10.1182/blood-2005-03-1214

Published: 2005

Journal Articles

Immunoglobulin Heavy Chain (IgH) Gene Somatic Hypermutation Status Using Homoduplex-Separated RT-PCR Products.

Melissa A. Melan, PhD, Kenneth A. Foon, MD, Stanley M. Marks, MD, Jeffrey A. Kant, MD PhD

Blood (2004) 104 (11): 4813.

https://doi.org/10.1182/blood.V104.11.4813.4813

Published: 2004

NARROW

Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials

MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR 2 Regimen

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia

Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIP™ Protein In Relapsed and Refractory CLL

A Randomized Controlled Trial of Spiritually-Focused Meditation In Patients Newly Diagnosed with Acute Leukemia.

Clearly defined response criteria evaluating treatment of CLL patients in clinical research trials

Phase II Study of Short Course CHOP-Rituximab Followed by 90-Y Ibritumomab Tiuxetan as First-Line Treatment for Follicular Lymphoma: An Update and Extension of Preliminary Findings on Predictors of Relapse.

Flow cytometric immunophenotyping for hematologic neoplasms

Final Results of Lower Dose Fludarabine (F) and Cyclophosphamide (C), and High Dose Rituximab (R), (FCR-Lite) for Patients with Untreated Chronic Lymphocytic Leukemia (CLL).

Generation of alpha-Type-1 Polarized Dendritic Cells as a Potent Immunogen in Patients with Chronic Lymphocytic Leukemia.

Interleukin-15 Upregulates the Expression of NK-Cell Activating Receptors and Concomitantly Increases the NK Cytotoxicity in Patients with Acute Myeloid Leukemia.

CD4+ CD25 high Regulatory T Cells in Newly Diagnosed Patients with Acute Myeloid Leukemia.

Efficacy of Mitoxantrone and Etoposide in Patients with Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy.

Early Clinical and Pharmacokinetic Results of Lower Dose Fludarabine and Cyclophosphamide, and High Dose Rituximab (FCR-Lite) for Patients with Untreated Chronic Lymphocytic Leukemia (CLL).

The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL

Phase II Trial of Abbreviated CHOP-Rituximab Followed by 90 Y Ibritumomab Tiuxetan (Zevalin) and Rituximab in Patients with Previously-Untreated Follicular Non-Hodgkin Lymphoma (NHL).

An Alternative Transcript of the PANE1 Gene Encodes a Minor Histocompatibility Antigen That Is Selectively Expressed in Resting CD19 + Cells and B-CLL.

Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules

Immunoglobulin Heavy Chain (IgH) Gene Somatic Hypermutation Status Using Homoduplex-Separated RT-PCR Products.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only